Morepen Laboratories Ratios

Morepen Laboratories Ltd Ratios

The Morepen Laboratories Ltd Ratios page provides a complete fundamental analysis of Morepen Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Morepen Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Morepen Laboratories Ltd (NSE: MOREPENLAB, BSE: 500288) is currently trading at ₹43.67, with a market capitalization of ₹23.99B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Morepen Laboratories Ltd remains a key stock for fundamental analysis using Morepen Laboratories Ltd Ratios.

Morepen Laboratories Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Morepen Laboratories Ltd P/E ratio currently stands at 21.70, making it one of the most tracked metrics in Morepen Laboratories Ltd Ratios.

Historically, the Morepen Laboratories Ltd P/E ratio has shown strong fluctuations:

• 2024: 21.70
• 2023: 22.36
• 2022: 33.35
• 2021: 18.71
• 2020: 14.94

The decline in Morepen Laboratories Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Morepen Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 2.27.

Historical P/B trend:

• 2024: 2.27
• 2023: 2.54
• 2022: 1.74
• 2021: 3.02

Morepen Laboratories Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Morepen Laboratories Ltd P/S ratio currently stands at 1.42, an important part of Morepen Laboratories Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 1.42
• 2023: 1.28
• 2022: 0.91
• 2021: 1.23

The rising Morepen Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.

Morepen Laboratories Ltd Price to Cash Flow Ratio (P/CF)

The Morepen Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 108.

Historical Morepen Laboratories Ltd Price to Cash Flow Ratio:

• 2024: 108
• 2023: 30.86
• 2022: 0
• 2021: 0
• 2020: 29.57

The rising Morepen Laboratories Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Morepen Laboratories Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Morepen Laboratories Ltd EV currently stands at ₹25.7B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 25.7B
• 2023: 21.27B
• 2022: 12.58B
• 2021: 19.89B

Morepen Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Morepen Laboratories Ltd EV/EBITDA ratio is currently 15.14, a key metric in Morepen Laboratories Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 15.14
• 2023: 14.14
• 2022: 16.47
• 2021: 12.99

Higher Morepen Laboratories Ltd EV/EBITDA suggests premium valuation.

Morepen Laboratories Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Morepen Laboratories Ltd D/E ratio is currently 0.09, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.09
• 2023: 0.03
• 2022: 0.03
• 2021: 0.23

Morepen Laboratories Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Morepen Laboratories Ltd ROE currently stands at 11.78%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.78
• 2023: 12.02
• 2022: 5.81
• 2021: 20.27

Morepen Laboratories Ltd maintains stable profitability levels.

Morepen Laboratories Ltd Ratios Analysis Summary

The Morepen Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Morepen Laboratories Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Morepen Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.